CClinicalTrials.gg
RecruitingNCT05781009Updated Feb 2, 2026

Pregnenolone for the Treatment of Alcohol Use Disorder

A Phase 2 interventional study of Pregnenolone and Placebo in Alcohol Use Disorder, sponsored by Yale University. Recruiting at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-02-02.

Sponsored by Yale University · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 9 months later.
Phase
Phase 2
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This Phase 2 randomized cotrolled trial (RCT) will assess the safety and efficacy of pregnenolone (PREG; 300 mg/day, b.i.d dosing) vs. placebo (PBO) over a 12 week treatment period, and at 1-month post-treatment follow-up in individuals with Alcohol Use Disorder (AUD).

Read the detailed description

In this Phase 2 single-site randomized controlled trial (RCT), men and women with Alcohol Use Disorder (AUD) will be enrolled in a 12 week trial with a 1-month follow-up assessment. Participants will be randomly assigned to 300mg pregnenolone (PREG) treatment b.i.d., or Placebo (PBO). All participants will be assessed 2x weekly and also receive behavior counseling to support recovery. The study aims to examine a) the safety and tolerability; b) efficacy on alcohol use outcomes; and c) effects on alcohol craving, anxiety, depression and physical well-being of 300mg PREG vs. PBO in men and women with AUD over the 12-week treatment period and at the 1-month follow up post-treatment period.

02

Conditions studied

  • Alcohol Use Disorder

Browse trials for

03

In context

Alcoholism

1,606 studies on the registry are indexed under Alcoholism; 329 are open to participants now.

This study's planned enrollment of 150 is above the median of 87 across 1,371 interventional studies indexed under Alcoholism.

Browse Alcoholism studies →

Lead sponsor

Yale University is the lead sponsor of 1,724 studies on the registry; 298 are open to participants now.

Of its 210 completed or terminated interventional studies of FDA-regulated products, 126 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Male and females, aged 18-70 years;
  • Regular weekly use of alcohol at least 3X weekly or more at treatment entry;
  • Must meet current DSM-5 criteria for moderate to severe Alcohol Use Disorders (AUDs) using SCID-I for DSM-5;
  • No health conditions that would impact trial participation as verified by screening and physical examination and absence of any of the exclusion criterions outlined below;
  • Able to read English and complete study evaluations;
  • Able to provide informed written and verbal consent.

Exclusion criteria

Exclusion Criteria:

  • Meet current criteria for moderate to severe substance use disorders from use of any other psychoactive substance, excluding nicotine and cannabis use disorder;
  • Current use of opioids;
  • Regular use of anticonvulsants, sedatives or hypnotics, oral prescription analgesics (other than non-steroidal anti-inflammatory drugs), topiramate, baclofen;
  • Regular use of steroidal supplements and steroid medications interacting with study medications based on clinical judgement of study physician (excluding hormonal contraceptives in women);
  • Psychotic or otherwise severely psychiatrically disabled (i.e., suicidal, homicidal, current mania);
  • Significant underlying medical conditions such as cerebral, renal, thyroid or cardiac pathology which in the opinion of study physician would preclude patient from fully cooperating or be of potential harm during the course of the study, but stable, prescribed anti-hypertensives. cardiovascular and diabetes medications will be allowed after review by study physician;
  • Any psychotic disorder or current Axis I psychiatric disorders requiring specific acute attention, including need for psychiatric medications, but stable, prescribed antidepressants and anti-anxiety medication to treat co-occurring psychiatric disorders will be allowed;
  • Women who are pregnant, nursing or refuse to use a reliable form of birth control (as assessed by urine pregnancy tests during initial medical evaluation, and assessed every two weeks during the course of the study).
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
150 participants (estimated)

Study arms

  • Active comparator
    patients receiving 300mg PREG

    Patients randomly assigned to receive 300mg of pregnenolone (PREG) daily.

    Drug: Pregnenolone

  • Placebo comparator
    placebo

    Patients randomly assigned to receive a placebo daily.

    Drug: Placebo

Interventions

  • DrugPregnenolone

    300mg

  • DrugPlacebo

    placebo

06

What researchers measure

Primary outcomes

  1. Percent of Subjects with no Heavy Drinking Days

    Pregnenolone versus Placebo treated subjects will be compared on any days of heavy drinking which is defined by 5 or more drinks per day in men and 4 or more drinks/day in women. This will be measured by the Percent of Subjects with no Heavy Drinking Days (PSNHDD) over a 12 week period.

    Time frame: 12 weeks

  2. Safety of pregnenolone

    The Systematic Assessment of Treatment Emergent Events (SAFTEE) Questionnaire will be used to assess adverse events weekly during the trial.

    Time frame: 12 weeks

Secondary outcomes

  1. Percent Heavy Drinking Days

    Percent of overall days with heavy drinking days (defined by 5 or more drinks per day in men and 4 or more drinks/day in women).

    Time frame: 12 weeks

  2. Percent Any Drinking Days

    Percent of any drinking days over a 12 week period.

    Time frame: 12 weeks

  3. Average Drinks per Day

    The average number of drinks consumed per day assessed weekly over the treatment period.

    Time frame: 12 weeks

07

Study locations

1 of 1 sites recruiting
  • The Yale Stress Center: Yale University
    New Haven, Connecticut 06519, United States
    • Rachel Hart, MS · Contact · rachel.hart@yale.edu · 203-737-4791
    • Verica Milivojevic, PhD · Contact · verica.milivojevic@yale.edu · 12037371176
    • Verica Milivojevic, PhD · Principal investigator
    • Rajita Sinha, PhD · Principal investigator
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05781009
Lead sponsor
Yale University
Collaborators
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Responsible party
Sponsor
First posted
Mar 23, 2023
Start date
Jan 8, 2024
Primary completion
Jul 31, 2028 (estimated)
Completion
Jul 31, 2028 (estimated)
Last update
Feb 2, 2026

Study contacts

Verica Milivojevic, PhD
Contact
verica.milivojevic@yale.edu
203-737-1176
Rajita Sinha, PHD
Contact
rajita.sinha@yale.edu
203-737-5805

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion